Clinical Trial

Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia

Study acronym: REBELLE
Recruiting
View on ClinicalTrials.gov →
Summary
The aim of the REBELLE cohort - bio-collection is to collect samples from patients with Chronic Lymphocytic Leukemia candidates or those exposed to BTK degraders to evaluate the mechanisms of resistance to these new molecules. To do this, an additional blood or bone marrow sample to those planned in the context of patient care or a residual lymph node biopsy sample will be collected after signing consent.
Protocol Amendment History 1 change
critical Phase changed: not applicable -> not specified 2026-04-23
Trial Details
NCT Number NCT07099443
Lead Sponsor Nantes University Hospital
Conditions Chronic Lymphocytic Leukemia, BTK Degraders
Enrollment 60 participants
Start Date 2025-10-09
Primary Completion 2039-09-15 (estimated)
Study Completion 2039-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-08